[go: up one dir, main page]

MX2019013148A - Compuestos heterociclicos biciclicos sustituidos como inhibidores de la nadph oxidasa. - Google Patents

Compuestos heterociclicos biciclicos sustituidos como inhibidores de la nadph oxidasa.

Info

Publication number
MX2019013148A
MX2019013148A MX2019013148A MX2019013148A MX2019013148A MX 2019013148 A MX2019013148 A MX 2019013148A MX 2019013148 A MX2019013148 A MX 2019013148A MX 2019013148 A MX2019013148 A MX 2019013148A MX 2019013148 A MX2019013148 A MX 2019013148A
Authority
MX
Mexico
Prior art keywords
oxidase inhibitors
nadph oxidase
heterocyclic compounds
bicyclic heterocyclic
substituted bicyclic
Prior art date
Application number
MX2019013148A
Other languages
English (en)
Inventor
Atmaram Gharat Laxmikant
Sundarlal Chaudhari Sachin
Thomas Abraham
Manish Shah Daisy
Khairatkar-Joshi Neelima
Kumar Sukeerthi
Mukhopadhyay Indranil
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of MX2019013148A publication Critical patent/MX2019013148A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de heteroarilo y heterocíclicos fusionados sustituidos, útiles como inhibidores de la nicotinamida adenina dinucleótido fosfato oxidasa (inhibidores de la NADPH oxidasa), procesos para su preparación, composiciones farmacéuticas que comprenden los compuestos, y el uso de los compuestos o las composiciones en el tratamiento o prevención de diversas enfermedades, afecciones y/o trastornos mediados por la NADPH oxidasa.(ver formula).
MX2019013148A 2017-05-04 2018-05-04 Compuestos heterociclicos biciclicos sustituidos como inhibidores de la nadph oxidasa. MX2019013148A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721015787 2017-05-04
PCT/IB2018/053121 WO2018203298A1 (en) 2017-05-04 2018-05-04 Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors

Publications (1)

Publication Number Publication Date
MX2019013148A true MX2019013148A (es) 2019-12-18

Family

ID=62245373

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013148A MX2019013148A (es) 2017-05-04 2018-05-04 Compuestos heterociclicos biciclicos sustituidos como inhibidores de la nadph oxidasa.

Country Status (16)

Country Link
US (1) US20200247800A1 (es)
EP (1) EP3619209A1 (es)
JP (1) JP2020518624A (es)
KR (1) KR20200013665A (es)
CN (1) CN110914263A (es)
AU (1) AU2018262528A1 (es)
BR (1) BR112019023109A2 (es)
CA (1) CA3062185A1 (es)
CL (1) CL2019003107A1 (es)
CO (1) CO2019013655A2 (es)
EA (1) EA201992343A1 (es)
MX (1) MX2019013148A (es)
PE (1) PE20191789A1 (es)
PH (1) PH12019502462A1 (es)
SG (1) SG11201910172VA (es)
WO (1) WO2018203298A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53043B2 (fr) 2018-10-01 2024-05-31 Genzyme Corp Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation
CN115215767B (zh) * 2021-04-16 2023-09-12 帕潘纳(北京)科技有限公司 制备2-氰基-3-乙氧基丙烯酸乙酯衍生物的方法
CN113292496B (zh) * 2021-05-17 2023-03-10 安徽联创生物医药股份有限公司 一种劳拉替尼中间体的合成方法
EP4363563A4 (en) * 2021-07-01 2025-05-14 Ionis Pharmaceuticals, Inc. Modulation of nox4 expression
CA3252551A1 (en) 2022-05-09 2023-11-16 Calliditas Therapeutics Suisse Sa NOX INHIBITORS INTENDED FOR USE IN THE TREATMENT OF ALPORT SYNDROME

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070082910A1 (en) * 2003-04-08 2007-04-12 Mitsubishi Pharma Corporation Specific nad(p)h oxidase inhibitor
JP2007133750A (ja) * 2005-11-11 2007-05-31 Canon Inc 情報処理方法及び情報処理装置
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
FR2929276B1 (fr) * 2008-04-01 2010-04-23 Servier Lab Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2166010A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166008A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
GB201104600D0 (en) * 2011-03-18 2011-05-04 Pronoxis Ab New compounds and medical uses
JP7105691B2 (ja) * 2015-11-25 2022-07-25 イーフェクター セラピューティクス， インコーポレイテッド Ｅｉｆ４ａ－阻害化合物およびそれに関連する方法

Also Published As

Publication number Publication date
PH12019502462A1 (en) 2020-06-29
JP2020518624A (ja) 2020-06-25
CN110914263A (zh) 2020-03-24
WO2018203298A1 (en) 2018-11-08
EP3619209A1 (en) 2020-03-11
KR20200013665A (ko) 2020-02-07
CL2019003107A1 (es) 2020-03-13
CA3062185A1 (en) 2018-11-08
SG11201910172VA (en) 2019-11-28
EA201992343A1 (ru) 2020-04-16
CO2019013655A2 (es) 2020-04-01
BR112019023109A2 (pt) 2020-05-26
AU2018262528A1 (en) 2019-11-21
PE20191789A1 (es) 2019-12-24
US20200247800A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
PH12019502462A1 (en) Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors
HK1245777A1 (zh) 用作nadph氧化酶抑制剂的氨基噻二唑衍生物
GEAP202415945A (en) Bicyclic heterocycles as fgfr inhibitors
WO2010035219A3 (en) Pyrazolo pyridine derivatives as nadph oxidase inhibitors
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
PH12017501921A1 (en) Novel compounds
EP4365179A3 (en) Novel rapamycin derivatives
EA201891917A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
MY204421A (en) Pyruvate kinase activators for use in treating blood disorders
SG10201909545XA (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
MY189761A (en) Quinazoline derivatives used to treat hiv
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
MY199124A (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
PH12015502248B1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
AU2012204982A8 (en) 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors
MX373186B (es) Nuevos derivados de 1-(4-pirimidinil)-1h-pirrolo[3,2-c]piridina como inhibidores de la cinasa inductora de nf-kappab.
WO2018209363A3 (en) PROPIONIC ACID DERIVATIVES AND ASSOCIATED METHODS OF USE
MX2017009600A (es) Derivados de 2-fenil-3h-imidazo[4,5-b]piridina utiles como inhibidores de actividad de receptor huerfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamifero.
HK1252245A1 (zh) 用於治疗癌症的核苷酸
PH12018500827A1 (en) 6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
MX2021015898A (es) Compuestos heterocíclicos bicíclicos como inhibidores de actividad de ofbcdin3d.
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
MX2023015246A (es) Compuestos pirimidinicos para usar como inhibidores de map4k1.
MY206575A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors